AveXis’ expects to start a Phase 3 clinical trial of its spinal muscular atrophy (SMA) gene therapy AVXS-101 in Europe in May. The STR1VE-EU trial (NCT03461289) is expected to include up to ... Read more
Treatment with Spinraza (nusinersen) induced significant and clinically relevant motor function improvement in children with later-onset spinal muscular atrophy (SMA), final results of a Phase 3 trial show. The ... Read more
A Phase 3 clinical trial to evaluating the safety and efficacy of an investigational gene replacement therapy by AveXis is now recruiting infants with spinal muscular atrophy type 1.
The trial ... Read more
Pin It on Pinterest